Table 2.
Anticoagulation treatment patterns at baseline
| Argentina (n = 949) | Brazil (n = 1041) | Chile (n = 976) | Mexico (n = 1140) | All (n = 4106) | |
|---|---|---|---|---|---|
| VKA, % | 26.3 | 19.8 | 53.9 | 18.6 | 29.1 |
| VKA + AP, % | 13.4 | 9.0 | 16.1 | 5.7 | 10.8 |
| FXaI, % | 8.0 | 16.3 | 6.9 | 17.0 | 12.3 |
| FXaI + AP, % | 3.2 | 4.8 | 3.3 | 3.6 | 3.7 |
| DTI, % | 6.0 | 3.3 | 1.6 | 6.9 | 4.5 |
| DTI + AP, % | 2.1 | 1.4 | 0.5 | 1.4 | 1.3 |
| AP, %a | 23.2 | 26.2 | 10.1 | 34.9 | 24.1 |
| No treatment | 17.8 | 19.2 | 7.6 | 12.0 | 14.1 |
Abbreviations: AP, antiplatelets; DTI, direct thrombin inhibitor; FXaI, Factor Xa inhibitor; VKA,vitamin K antagonist.
The P‐value for at least one country having a different treatment mix is < 0.001.
a
AP alone.